|
|
ESR1 |
estrogen receptor 1 |
- Nuclear signaling by ERBB4
- PIP3 activates AKT signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
- Ovarian tumor domain proteases
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- RUNX1 regulates estrogen receptor mediated transcription
- ESR-mediated signaling
- RUNX1 regulates transcription of genes involved in WNT signaling
- Regulation of RUNX2 expression and activity
- Regulation of RUNX2 expression and activity
- Extra-nuclear estrogen signaling
- Estrogen-dependent gene expression
- Mitochondrial unfolded protein response (UPRmt)
- Developmental Lineage of Mammary Gland Luminal Epithelial Cells
- Developmental Lineage of Mammary Gland Alveolar Cells
|
- Diethylstilbestrol
- Chlorotrianisene
- Conjugated estrogens
- Desogestrel
- Levonorgestrel
- Progesterone
- Lindane
- Raloxifene
- Toremifene
- Medroxyprogesterone acetate
- Testosterone
- Mitotane
- Estrone
- Tamoxifen
- Hexachlorophene
- Estradiol
- Ethynodiol diacetate
- Dobutamine
- Clomifene
- Dienestrol
- Fulvestrant
- Norgestimate
- Ethinylestradiol
- Melatonin
- Trilostane
- Naloxone
- Fluoxymesterone
- Estramustine
- Mestranol
- Danazol
- Oxybenzone
- Allylestrenol
- Zinc
- Genistein
- Prasterone
- Benzophenone
- Equilin
- Compound 19
- Resveratrol
- Compound 18
- Phthalic Acid
- Pyrazole
- Stanolone
- Naringenin
- Compound 4-D
- 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
- Quercetin
- Afimoxifene
- 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
- Estriol
- Estrone sulfate
- Quinestrol
- Phenolphthalein
- Permethrin
- Ospemifene
- AP1081
- Custirsen
- NP-50301
- CHF 4227
- TAS-108
- Lasofoxifene
- Arzoxifene
- Elacestrant
- Bazedoxifene
- Methyltestosterone
- beta-Naphthoflavone
- 17-METHYL-17-ALPHA-DIHYDROEQUILENIN
- din-6-yl)phenol
- [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
- 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL
- (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
- (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
- (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL
- 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
- 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
- Hexestrol
- dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate
- Erteberel
- N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE
- (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
- 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol
- 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
- DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE
- 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
- 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL
- 2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol
- Tibolone
- Eugenol
- Synthetic Conjugated Estrogens, A
- Synthetic Conjugated Estrogens, B
- Polyestradiol phosphate
- Norethynodrel
- Octocrylene
- Homosalate
- Enzacamene
- Zeranol
- Ractopamine
- Gestrinone
- Estetrol
- Propyl Gallate
- Ormeloxifene
- 2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol
- Testosterone cypionate
- Testosterone enanthate
- Stanolone acetate
- Estradiol acetate
- Estradiol benzoate
- Estradiol cypionate
- Estradiol dienanthate
- Estradiol valerate
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
- Estriol tripropionate
- Fluoroestradiol F-18
|
|
|
|
EZR |
ezrin |
- Netrin-1 signaling
- Recycling pathway of L1
- Recycling pathway of L1
- Sensory processing of sound by inner hair cells of the cochlea
- Sensory processing of sound by outer hair cells of the cochlea
|
|
|
|
|
FBXW2 |
F-box and WD repeat domain containing 2 |
- Association of TriC/CCT with target proteins during biosynthesis
- Neddylation
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
|
FER |
FER tyrosine kinase |
|
|
|
|
|
FERMT2 |
FERM domain containing kindlin 2 |
- Cell-extracellular matrix interactions
- RAC1 GTPase cycle
- RAC3 GTPase cycle
|
|
|
|
|
FHIT |
fragile histidine triad diadenosine triphosphatase |
|
- Adenosine monotungstate
- Ado-P-Ch2-P-Ps-Ado
|
- Small cell lung cancer
- Non-small cell lung cancer
|
|
|
FHL2 |
four and a half LIM domains 2 |
- PPARA activates gene expression
|
|
|
|
|
FLT1 |
fms related receptor tyrosine kinase 1 |
- Neurophilin interactions with VEGF and VEGFR
- VEGF binds to VEGFR leading to receptor dimerization
|
- Sorafenib
- Sunitinib
- Vatalanib
- TG-100801
- OSI-930
- Denibulin
- Linifanib
- IMC-1C11
- Pazopanib
- Axitinib
- N-(4-chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide
- Regorafenib
- Lenvatinib
- Nintedanib
- Polaprezinc
- Foreskin fibroblast (neonatal)
- Tivozanib
- Fostamatinib
- Selpercatinib
|
|
|
|
FLT3 |
fms related receptor tyrosine kinase 3 |
- PI3K Cascade
- PIP3 activates AKT signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- FLT3 Signaling
- FLT3 Signaling
- STAT5 Activation
- FLT3 mutants bind TKIs
- STAT5 activation downstream of FLT3 ITD mutants
- KW2449-resistant FLT3 mutants
- semaxanib-resistant FLT3 mutants
- crenolanib-resistant FLT3 mutants
- gilteritinib-resistant FLT3 mutants
- lestaurtinib-resistant FLT3 mutants
- midostaurin-resistant FLT3 mutants
- pexidartinib-resistant FLT3 mutants
- ponatinib-resistant FLT3 mutants
- quizartinib-resistant FLT3 mutants
- sorafenib-resistant FLT3 mutants
- sunitinib-resistant FLT3 mutants
- tandutinib-resistant FLT3 mutants
- linifanib-resistant FLT3 mutants
- tamatinib-resistant FLT3 mutants
- Signaling by FLT3 ITD and TKD mutants
- Signaling by FLT3 ITD and TKD mutants
- Negative regulation of FLT3
- FLT3 signaling through SRC family kinases
- FLT3 signaling through SRC family kinases
- FLT3 signaling by CBL mutants
|
- Sorafenib
- Sunitinib
- XL999
- Tandutinib
- Linifanib
- Lestaurtinib
- Midostaurin
- Ponatinib
- Nintedanib
- Pacritinib
- Tivozanib
- Fostamatinib
- Gilteritinib
- Brigatinib
- Fedratinib
- Amuvatinib
- Quizartinib
- Pexidartinib
- Pralsetinib
|
- Acute myeloid leukemia (AML)
|
|
|
FOXO1 |
forkhead box O1 |
- AKT phosphorylates targets in the nucleus
- Regulation of gene expression in beta cells
- AKT-mediated inactivation of FOXO1A
- Constitutive Signaling by AKT1 E17K in Cancer
- MAPK6/MAPK4 signaling
- Interleukin-4 and Interleukin-13 signaling
- Regulation of localization of FOXO transcription factors
- FOXO-mediated transcription of cell death genes
- FOXO-mediated transcription of cell death genes
- FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
- FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
- Regulation of FOXO transcriptional activity by acetylation
- Regulation of FOXO transcriptional activity by acetylation
- FOXO-mediated transcription of cell cycle genes
- FOXO-mediated transcription of cell cycle genes
|
|
- Alveolar rhabdomyosarcoma
|
|
|
FOXO4 |
forkhead box O4 |
- AKT phosphorylates targets in the nucleus
- Constitutive Signaling by AKT1 E17K in Cancer
- Ub-specific processing proteases
- Regulation of localization of FOXO transcription factors
- FOXO-mediated transcription of cell death genes
- FOXO-mediated transcription of cell death genes
- FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
- FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
- Regulation of FOXO transcriptional activity by acetylation
- FOXO-mediated transcription of cell cycle genes
- FOXO-mediated transcription of cell cycle genes
- Cardiogenesis
|
|
|
|
|
FSCN1 |
fascin actin-bundling protein 1 |
- Interleukin-4 and Interleukin-13 signaling
|
|
|
|
|
FUS |
FUS RNA binding protein |
- mRNA Splicing - Major Pathway
- Processing of Capped Intron-Containing Pre-mRNA
|
|
- Myxoid liposarcoma
- Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
|
|
|
FYN |
FYN proto-oncogene, Src family tyrosine kinase |
- GPVI-mediated activation cascade
- Signaling by ERBB2
- PIP3 activates AKT signaling
- Signaling by SCF-KIT
- Signaling by SCF-KIT
- Regulation of KIT signaling
- Nef and signal transduction
- Cell surface interactions at the vascular wall
- FCGR activation
- PECAM1 interactions
- Constitutive Signaling by Aberrant PI3K in Cancer
- DAP12 signaling
- DAP12 signaling
- EPH-Ephrin signaling
- Role of LAT2/NTAL/LAB on calcium mobilization
- Nephrin family interactions
- Nephrin family interactions
- NCAM signaling for neurite out-growth
- NCAM signaling for neurite out-growth
- Co-stimulation by CD28
- CD28 dependent PI3K/Akt signaling
- CD28 dependent Vav1 pathway
- Co-inhibition by CTLA4
- EPHB-mediated forward signaling
- EPHB-mediated forward signaling
- EPHA-mediated growth cone collapse
- EPHA-mediated growth cone collapse
- Ephrin signaling
- Ephrin signaling
- EPH-ephrin mediated repulsion of cells
- Sema3A PAK dependent Axon repulsion
- SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
- SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
- CRMPs in Sema3A signaling
- CRMPs in Sema3A signaling
- VEGFA-VEGFR2 Pathway
- Dectin-2 family
- CD209 (DC-SIGN) signaling
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Platelet Adhesion to exposed collagen
- Reelin signalling pathway
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- FCGR3A-mediated IL10 synthesis
- FCGR3A-mediated phagocytosis
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by CSF1 (M-CSF) in myeloid cells
- FLT3 signaling through SRC family kinases
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
|
- Dasatinib
- Triglyme
- Fostamatinib
- Zotiraciclib
|
|
|
|
GLIS2 |
GLIS family zinc finger 2 |
|
|
- Nephronophthisis-medullary cystic kidney disease, including; Nephronophthisis (NPH) ; Nephronophthisis-like nephropathy 1; Medullary cystic kidney disease 1; Medullary cystic kidney disease 2 (MSKD2)
|
|
|
GNA13 |
G protein subunit alpha 13 |
- NRAGE signals death through JNK
- G alpha (12/13) signalling events
- Thromboxane signalling through TP receptor
- Thrombin signalling through proteinase activated receptors (PARs)
- Thrombin signalling through proteinase activated receptors (PARs)
- CDC42 GTPase cycle
- RAC1 GTPase cycle
|
|
|
|
|
GRIK2 |
glutamate ionotropic receptor kainate type subunit 2 |
- Activation of Na-permeable kainate receptors
- Activation of Ca-permeable Kainate Receptor
|
- Glutamic acid
- Butabarbital
- Butalbital
- Topiramate
- Talbutal
- Pentobarbital
- Secobarbital
- Metharbital
- Thiopental
- Primidone
- Methylphenobarbital
- Phenobarbital
- Amobarbital
- Aprobarbital
- Butobarbital
- Heptabarbital
- Hexobarbital
- Barbital
- Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione
- Domoic Acid
- Quisqualic acid
- 2s,4r-4-Methylglutamate
|
- Nonsyndromic autosomal recessive mental retardation (NS-ARMR)
|
|
|
GRIN1 |
glutamate ionotropic receptor NMDA type subunit 1 |
- EPHB-mediated forward signaling
- EPHB-mediated forward signaling
- Unblocking of NMDA receptors, glutamate binding and activation
- Unblocking of NMDA receptors, glutamate binding and activation
- Ras activation upon Ca2+ influx through NMDA receptor
- RAF/MAP kinase cascade
- Neurexins and neuroligins
- Synaptic adhesion-like molecules
- Assembly and cell surface presentation of NMDA receptors
- Assembly and cell surface presentation of NMDA receptors
- Negative regulation of NMDA receptor-mediated neuronal transmission
- Long-term potentiation
|
- Glutamic acid
- Tramadol
- Enflurane
- Atomoxetine
- Pentobarbital
- Methadone
- Secobarbital
- Meperidine
- Dextropropoxyphene
- Acamprosate
- Donepezil
- Guaifenesin
- Memantine
- Memantine
- Orphenadrine
- Phenobarbital
- Aripiprazole
- Prasterone
- 5,7-Dichlorokynurenic acid
- D-Serine
- Cycloleucine
- Milnacipran
- CNS-5161
- Acetylcysteine
- Ketobemidone
- Gavestinel
- Agmatine
- Ifenprodil
- Magnesium acetate tetrahydrate
- Magnesium carbonate
- Esketamine
- Fluciclovine (18F)
|
|
|
|
GRIN2D |
glutamate ionotropic receptor NMDA type subunit 2D |
- Unblocking of NMDA receptors, glutamate binding and activation
- Unblocking of NMDA receptors, glutamate binding and activation
- Ras activation upon Ca2+ influx through NMDA receptor
- RAF/MAP kinase cascade
- Neurexins and neuroligins
- Synaptic adhesion-like molecules
- Assembly and cell surface presentation of NMDA receptors
- Assembly and cell surface presentation of NMDA receptors
- Negative regulation of NMDA receptor-mediated neuronal transmission
- Long-term potentiation
|
- Glutamic acid
- Tramadol
- Enflurane
- Atomoxetine
- Pentobarbital
- Methadone
- Secobarbital
- Meperidine
- Dextropropoxyphene
- Acamprosate
- Donepezil
- Guaifenesin
- Memantine
- Orphenadrine
- Phenobarbital
- Aripiprazole
- Tenocyclidine
- Prasterone
- Milnacipran
- Acetylcysteine
- Ketobemidone
- Gavestinel
- Magnesium acetate tetrahydrate
- Magnesium carbonate
- Esketamine
- Fluciclovine (18F)
|
|
|
|
GSK3B |
glycogen synthase kinase 3 beta |
- Degradation of beta-catenin by the destruction complex
- Beta-catenin phosphorylation cascade
- AKT phosphorylates targets in the cytosol
- Regulation of HSF1-mediated heat shock response
- CRMPs in Sema3A signaling
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- B-WICH complex positively regulates rRNA expression
- Signaling by GSK3beta mutants
- CTNNB1 S33 mutants aren't phosphorylated
- CTNNB1 S37 mutants aren't phosphorylated
- CTNNB1 S45 mutants aren't phosphorylated
- CTNNB1 T41 mutants aren't phosphorylated
- APC truncation mutants have impaired AXIN binding
- AXIN missense mutants destabilize the destruction complex
- Truncations of AMER1 destabilize the destruction complex
- Degradation of GLI2 by the proteasome
- GLI3 is processed to GLI3R by the proteasome
- Constitutive Signaling by AKT1 E17K in Cancer
- Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
- Ubiquitin-dependent degradation of Cyclin D
- Regulation of RUNX2 expression and activity
- Maturation of nucleoprotein
- Maturation of nucleoprotein
- GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2
- Transcriptional and post-translational regulation of MITF-M expression and activity
- GSK3B-mediated proteasomal degradation of PD-L1(CD274)
|
- Lithium cation
- 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione
- SB-409513
- AR-AO-14418
- Staurosporine
- Indirubin-3'-monoxime
- 6-bromoindirubin-3'-oxime
- Alsterpaullone
- Phosphoaminophosphonic Acid-Adenylate Ester
- 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole
- 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione
- (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
- N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
- 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
- 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2'H-2,3'-biindol-2'-one
- N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide
- 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
- ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
- (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
- Fostamatinib
- Tideglusib
- Lithium citrate
- Lithium succinate
- Lithium carbonate
|
|